magnolol has been researched along with oxidopamine in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CF; Chueh, FS; Chueh, FY; Hsieh, MT; Lin, MT; Lin, SM | 1 |
| Chan, MH; Chen, HH; Lin, SC | 1 |
| Hiratsuka, A; Izawa, T; Masuda, Y; Nishiyama, T; Ogura, K; Ohnuma, T | 1 |
3 other study(ies) available for magnolol and oxidopamine
| Article | Year |
|---|---|
Catecholaminergic mechanisms-mediated hypothermia induced by magnolol in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; alpha-Methyltyrosine; Animals; Anti-Anxiety Agents; Biphenyl Compounds; Body Temperature; Catecholamines; Colon; Dopamine; Dopamine Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epinephrine; Homovanillic Acid; Hypothalamus; Hypothermia, Induced; Injections, Intraperitoneal; Injections, Intraventricular; Levodopa; Lignans; Male; Norepinephrine; Oxidopamine; Rats; Rats, Sprague-Dawley | 1998 |
Protective and restorative effects of magnolol on neurotoxicity in mice with 6-hydroxydopamine-induced hemiparkinsonism.
Topics: Animals; Biphenyl Compounds; Corpus Striatum; Disease Models, Animal; Drug Administration Schedule; Lignans; Male; Mice; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Tyrosine 3-Monooxygenase | 2011 |
Magnolol protects PC12 cells from hydrogen peroxide or 6-hydroxydopamine induced cytotoxicity.
Topics: Animals; Biphenyl Compounds; Catalase; Cell Death; Cell Survival; Hydrogen Peroxide; Lignans; NAD(P)H Dehydrogenase (Quinone); Oxidopamine; PC12 Cells; Protective Agents; Rats | 2019 |